(Q40442161)

20 September 2017

title

Suppressive effect of ursodeoxycholic acid on type IIA phospholipase A2 expression in HepG2 cells (English)

1 reference

20 September 2017

Tadashi Ikegami

1

1 reference

20 September 2017

Yasushi Matsuzaki

2

1 reference

20 September 2017

Sugano Fukushima

3

1 reference

20 September 2017

Junichi Shoda

4

1 reference

20 September 2017

Jean Luc Olivier

5

1 reference

20 September 2017

Bernard Bouscarel

6

1 reference

20 September 2017

Naomi Tanaka

7

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 April 2005

1 reference

20 September 2017

1 reference

20 September 2017

volume

41

1 reference

20 September 2017

issue

4

1 reference

20 September 2017

page(s)

896-905

1 reference

Prevention by inhibitors of arachidonic acid cascade of liver carcinogenesis, cirrhosis and oxidative DNA damage caused by a choline-deficient, L-amino acid-defined diet in rats.

20 September 2017

cites work

1 reference

Gallbladder emptying determines early gallstone clearance after shock-wave lithotripsy.

21 January 2018

1 reference

Transcriptional regulation of inflammatory secreted phospholipases A(2).

21 January 2018

1 reference

Prostaglandins: Modulators of Renal Function and Pressor Resistance in Chronic Liver Disease*

21 January 2018

1 reference

7 January 2021

Effects of prostaglandin inhibition on systemic and hepatic hemodynamics in patients with cirrhosis of the liver.

1 reference

7 January 2021

Increased synthesis of systemic prostacyclin in cirrhotic patients

1 reference

7 January 2021

Systemic and renal production of thromboxane A2 and prostacyclin in decompensated liver disease and hepatorenal syndrome

1 reference

7 January 2021

Liver cirrhosis induces renal and liver phospholipase A2 activity in rats

1 reference

7 January 2021

Functional renal failure and haemorrhagic gastritis associated with endotoxaemia in cirrhosis

1 reference

7 January 2021

Cysteinyl leukotrienes in the urine of patients with liver diseases

1 reference

7 January 2021

The role of prostacyclin in patients with portal hypertension

1 reference

7 January 2021

Inhibition by acetylsalicylic acid, a cyclo-oxygenase inhibitor, and p-bromophenacylbromide, a phospholipase A2 inhibitor, of both cirrhosis and enzyme-altered nodules caused by a choline-deficient, L-amino acid-defined diet in rats.

1 reference

7 January 2021

Immunosuppressive properties of chenodeoxycholic and ursodeoxycholic acids in the mouse

1 reference

7 January 2021

A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation

1 reference

7 January 2021

A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group

1 reference

7 January 2021

Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients

1 reference

7 January 2021

Increased biliary group II phospholipase A2 and altered gallbladder bile in patients with multiple cholesterol stones

1 reference

7 January 2021

Effects of long-term ursodeoxycholate administration on expression levels of secretory low-molecular-weight phospholipases A2 and mucin genes in gallbladders and biliary composition in patients with multiple cholesterol stones

1 reference

7 January 2021

The chemopreventive role of ursodeoxycholic acid in azoxymethane-treated rats: suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue

1 reference

7 January 2021

Signal transduction and hepatocellular bile acid transport: cross talk between bile acids and second messengers

1 reference

7 January 2021

Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction

1 reference

7 January 2021

Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B

1 reference

7 January 2021

Positive and negative hepatic regulation of the human type II phospholipase A2 gene

1 reference

7 January 2021

Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited

1 reference

7 January 2021

Improvement of peripheral blood lymphocyte subsets in primary biliary cirrhosis after ursodeoxycholic acid therapy

1 reference

7 January 2021

Effects of bile acids on the humoral immune response: a mechanistic approach

1 reference

7 January 2021

Bile acid hydrophobicity is correlated with induction of apoptosis and/or growth arrest in HCT116 cells

1 reference

7 January 2021

Role of cytokines in ethanol-induced cytotoxicity in vitro in Hep G2 cells

1 reference

7 January 2021

Does ursodeoxycholic acid mediate immunomodulatory and anti-inflammatory effects in patients with primary sclerosing cholangitis?

1 reference

7 January 2021

Identification of a nuclear receptor for bile acids

1 reference

7 January 2021

Bile acids: natural ligands for an orphan nuclear receptor

1 reference

7 January 2021

Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor.

1 reference

7 January 2021

Bile acid regulation of gene expression: roles of nuclear hormone receptors.

1 reference

7 January 2021

Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor

1 reference

7 January 2021

Potentiation of tumor necrosis factor alpha-induced secreted phospholipase A2 (sPLA2)-IIA expression in mesangial cells by an autocrine loop involving sPLA2 and peroxisome proliferator-activated receptor alpha activation.

1 reference

7 January 2021

Induction of secreted type IIA phospholipase A2 gene transcription by interleukin-1beta. Role of C/EBP factors

1 reference

7 January 2021

Functional modulation of the glucocorticoid receptor and suppression of NF-kappaB-dependent transcription by ursodeoxycholic acid

1 reference

7 January 2021

Attenuation of ischemia and reperfusion injury of canine livers by inhibition of type II phospholipase A2 with LY329722.

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.20630

1 reference

20 September 2017

1 reference